6 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
| FY | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| 2025 | $2M | -$10M | 1.2% | -465.4% | -$4M | — | $7M |
| 2024 | $9M | -$12M | 42.9% | -137.0% | -$8M | — | $2M |
| 2023 | $10M | -$11M | 51.4% | -112.5% | -$6M | — | $2M |
| 2022 | — | -$10M | — | — | -$6M | — | $15M |
| 2021 | — | -$9M | — | — | -$11M | $3M | $28M |
| 2020 | — | -$5M | — | — | -$288806 | — | $695909 |
| Quarter | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| Mar '26 | $156009 | -$2M | 45.9% | -1627.1% | — | — | $3M |
| Dec '25 | $51761 | -$5M | -1056.9% | -5192.9% | -$916923 | — | $7M |
| Sep '25 | $106592 | -$3M | -91.9% | -2655.2% | -$2M | — | — |
| Jun '25 | $713135 | -$1M | 37.7% | -255.4% | — | — | — |
| Mar '25 | $1M | -$2M | 37.8% | -154.9% | — | — | — |
| Dec '24 | $1M | -$6M | 10.3% | -395.8% | -$4M | — | $2M |
| Sep '24 | $3M | -$1M | 41.6% | -64.1% | -$1M | — | $2M |
| Jun '24 | $3M | -$2M | 50.3% | -76.2% | -$2M | — | $2M |
| Mar '24 | $2M | -$3M | 56.3% | -131.0% | -$2M | — | $2M |
| Dec '23 | — | -$3M | — | — | $345141 | — | $2M |
| Sep '23 | — | -$2M | — | — | -$2M | — | $3M |
| Jun '23 | — | -$3M | — | — | -$2M | — | $2M |
| Mar '23 | — | -$2M | — | — | -$3M | — | $4M |
| Dec '22 | — | -$2M | — | — | — | — | $15M |
| Sep '22 | — | -$3M | — | — | — | $3M | $21M |
| Jun '22 | — | -$3M | — | — | — | $3M | $24M |
| Mar '22 | — | -$2M | — | — | — | $3M | $26M |
| Dec '21 | — | -$2M | — | — | -$1M | $3M | $28M |
| Sep '21 | — | -$2M | — | — | -$6M | — | $10M |
| Jun '21 | — | -$1M | — | — | — | $3M | $13M |
How the market has priced ISPC against its own fundamentals since 2023-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
Over the past 5 years, iSpecimen Inc.'s revenue has declined 55.9% per year. These are computed facts, not advice.
As of FY2025, iSpecimen Inc. reported — of total debt against $7M of cash; operating income covered interest expense -4606.4×.
In FY2025, gross margin was 1.2%, operating margin -465.4%, and net margin -543.7%.
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.